Relacorilant: Side Effects, Uses & Monitoring
Facts extracted from current FDA product labeling for Relacorilant. Educational only — not medical advice.
Labeled uses
LIFYORLI is indicated in combination with nab-paclitaxel for the treatment of adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior systemic treatment regimens, at least one of which included bevacizumab [see Clinical Studies (14 )] .
Source: FDA labeling via NIH DailyMed (set 6fcebfb5…). Not affiliated with FDA or NIH.
Medical disclaimer: Always consult a qualified healthcare professional about any medication.